Invokana is a brand-name medication prescribed to improve glycemic control in adults with type 2 diabetes [1]. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors [2].
How does Invokana work for type 2 diabetes?
Invokana, with the active ingredient canagliflozin, works by blocking the reabsorption of glucose in the kidneys. This action leads to more glucose being excreted in the urine, thereby lowering blood glucose levels [1][2]. It is typically used in conjunction with diet and exercise, and may be prescribed alone or with other diabetes medications [1].
What is the history of Invokana?
Invokana was first approved by the U.S. Food and Drug Administration (FDA) in March 2013 [3]. Its approval marked the introduction of the SGLT2 inhibitor class to the market [4].
When does Invokana's patent expire?
The patent landscape for Invokana is complex, involving multiple patents covering the drug, its uses, and manufacturing processes. Information on specific patent expiry dates and any associated litigation can be found on specialized patent tracking resources such as DrugPatentWatch.com [5]. Understanding patent expiry is crucial for the potential market entry of generic versions.
Are there generic versions of Invokana available?
As of now, the availability of generic versions of Invokana depends on the expiry of its patents and any subsequent regulatory approvals. Patent expirations can pave the way for the introduction of biosimilars or generics, which can impact drug pricing and accessibility [5].
What are the potential side effects of Invokana?
Common side effects associated with Invokana include urinary tract infections, yeast infections, and increased urination [1]. More serious, though less common, side effects have been reported, including dehydration, kidney problems, Fournier's gangrene (a rare but serious infection of the genitals and the area from the groin to the tailbone), and potential links to lower limb amputations [1][6]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Invokana compare to other diabetes medications?
Invokana is one of several SGLT2 inhibitors available for type 2 diabetes management. Other medications in this class include empagliflozin (Jardiance) and dapagliflozin (Farxiga) [2]. These drugs share a similar mechanism of action but may differ in their clinical trial data, side effect profiles, and approved indications [2][7]. Invokana has also been studied for its potential cardiovascular and renal benefits in certain patient populations [6][8].
What is the typical dosage and cost of Invokana?
Invokana is usually taken once daily and is available in 100 mg and 300 mg strengths [1]. The cost of Invokana can vary significantly depending on insurance coverage, pharmacy, and geographic location. Patients often explore cost-saving options through patient assistance programs or by comparing prices at different pharmacies [9].
What is the clinical data supporting Invokana's use?
Clinical trials have demonstrated Invokana's efficacy in lowering HbA1c levels, fasting plasma glucose, and body weight in adults with type 2 diabetes [1][8]. Furthermore, studies have indicated potential benefits for cardiovascular health, such as reducing the risk of major adverse cardiovascular events in some patients, and for slowing the progression of kidney disease in individuals with type 2 diabetes and chronic kidney disease [6][8].
---
Sources:
[1] https://www.invokana.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042342/
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/invokana-canagliflozin-drug-safety-communication-information
[4] https://www.nejm.org/doi/full/10.1056/NEJMp1304277
[5] https://www.drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181062/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301479/
[8] https://www.nejm.org/doi/full/10.1056/NEJMoa1804319
[9] https://www.goodrx.com/invokana